Sentences with phrase «cancer vaccine»

We aim to do this by enabling public awareness programs, screening and related women's health clinics and by providing cervical cancer vaccine to women who do not have access to it.

They aim to do this by enabling public awareness programs, screening and related women's health clinics and by providing cervical cancer vaccine to women who do not have access to it.

DHHS BARDA Contract, 2006, 15,000,000 PI - Transcutaneous Immunization for Tetanus Booster, 1998, NIAID Phase 1 SBIR, $ 100,000 PI - Transcutaneous Immunization for DNA, 1998, NIAID Phase 1 SBIR, $ 100,000 HIV RAD: Structural approaches to vaccine development, 2001, NIH, $ 340,000 PI - Transcutaneous Immunization for Tetanus Booster, 2002, NIAID Phase 2 SBIR, $ 851,767 Development of Broad Platform Immunostimulatory Cancer Vaccine, 2002, NIST, $ 3,467,618 Skin Immunization with SIV and HIV Antigen, 2002, NIAID SBIR, $ 399,790 Transcutaneous Immunization for Tetanus Booster, 2003, NIAID Phase 2 SBIR, $ 811,042

If you can accept it as a much smaller scale puzzle game then Big Pharma is actually really good, and while you might find yourself tiring of it quite quickly the hours you do spend spinning machines around and planning out new production lines are satisfying, especially when you first begin putting together the vast collection of equipment and belts required to create the most powerful drugs, such as a cancer vaccine.

Here, we report the first clinical trial in any species of a tumor RNA loaded CD40 - B cancer vaccine, performed in the setting of minimal residual disease.

Sorenmo KU, Krick E, Coughlin CM, Overley B, Gregor TP, et al. (2011) CD40 - Activated B Cell Cancer Vaccine Improves Second Clinical Remission and Survival in Privately Owned Dogs with Non-Hodgkin's Lymphoma.

-- «Mammaglobin — A Immunogenicity in Canine Mammary Cancer Vaccine Development,» led by Dr. R. Curtis Bird, Department of Pathobiology.

The Merck vaccine ii Gardasil cervical cancer vaccine introduced in 2006 and mandated for elementary school boys, brought overdue attention to the unethical, dishonest marketing of vaccines.

Nigerian Doctor Who Introduced Cervical Cancer Vaccine In Greenland Honoured By Denmark Queen.

Two Wisconsin sisters have filed a federal claim, saying they believe a cervical cancer vaccine caused their ovaries to stop producing eggs.

He is chief of hematological malignancies and director of the Cancer Vaccine Program at the Beth Israel Deaconess Medical Center in Boston.

Another type of cancer vaccine is intended as therapy for those who already have cancer.

«Based on the clinical evidence we've gathered over the past decade in our cancer vaccine trials,» Old said, «and in light of data from a variety of trials by others within the field, we believe therapeutic cancer vaccines will increasingly emerge as one of the safest and most powerful ways to combat a variety of cancers.»

Infection - Mimicking Polymers as a Cancer Vaccine David J. Mooney, PhD, School of Applied Engineering and Wyss Institute for Biologically Inspired Engineering, Harvard University

But CRI Clinical Investigator Dr. Ian Frazer is modest about his contribution to the development of the breakthrough cervical cancer vaccine.

NEW YORK, NY — April 30, 2010 — The Cancer Research Institute celebrates yesterday's announcement of the first therapeutic cancer vaccine to receive approval from the U.S. Food and Drug Administration.

This work led to the therapeutic cancer vaccine GVAX.

The Institute is host to over 300 researchers, students, and support staff and lays claim to global, world - changing discoveries such as the first cervical cancer vaccine.

«Novel cancer vaccine holds promise against ovarian cancer, mesothelioma.»

«We have created a potentially much less expensive approach to making a therapeutic cancer vaccine that, while targeting a single tumor antigen, generates an immune response against multiple antigens.

Most recently, CRI has launched a new «venture philanthropy» program called the Cancer Vaccine Acceleration Fund (CVAF) as a means to catalyze development of next - generation therapeutic cancer vaccines and other immunotherapies by helping to address the critical shortage of capital available for early stage clinical trials.

A breast cancer vaccine developed at the School of Medicine is safe in patients with metastatic breast cancer, results of an early clinical trial indicate.

First, in 2001, CRI formed a partnership with the Ludwig Institute for Cancer Research to develop the Cancer Vaccine Collaborative (CVC)-- a centralized, academic, global network of clinical trial sites, immune monitoring laboratories, and clinic - grade, GMP cancer vaccine production facilities.

CRI Scientific Advisory Council director Lloyd J. Old, M.D., a pioneer responsible for many seminal discoveries in the field, is a senior expert in tumor immunology who for the past four decades has guided the scientific vision for CRI and who currently leads the Institute's global cancer vaccine research programs.

Turnstone's therapeutic platform is a first - in - class, tumor - targeted oncolytic vaccine that combines potent tumor - killing effects of oncolytic viruses with the benefits of a cancer vaccine that harnesses the patient's own immune system to fight disease in a sustainable manner.

A therapeutic cervical cancer vaccine was developed and tested in women with advanced disease.

Ralph Steinman, a recent winner who passed away from pancreatic cancer, was so engrossed in his cancer vaccine research that he developed and tested an experimental treatment on himself in the years building up to the award [source: Altman and Wade].

While a co-founder of the cancer vaccine company Calviri, she is also the VP of Research at HealthTell, Inc., which is developing global measurements of immune health.

Lander is a cofounder of Millennium Pharmaceuticals, Infinity Pharmaceuticals, Verastem, and the cancer vaccine startup Neon Therapeutics.

A new pancreatic cancer vaccine being tested in clinical trials aims to restore the power of a patient's immune system.

2000 Johns Hopkins Cancer Center researchers develop a pancreatic cancer vaccine and prove it activates immune cells against pancreatic tumor cells.

Padmanee Sharma, M.D., Ph.D., a member of the CRI / Ludwig Cancer Vaccine Collaborative (CVC) at The University of Texas MD Anderson Cancer Center, has conducted innovative studies testing the effects of anti-CTLA-4 checkpoint blockade in the pre-surgical setting.

The new phase three study of the cervical cancer vaccine is needed for the FDA to consider approving it for more widespread use, said Ghamande, a principal investigator on the trial.

A new UC San Francisco study has shown that a cancer - killing («oncolytic») virus currently in clinical trials may function as a cancer vaccine — in addition to killing some cancer cells directly, the virus alerts the immune system to the presence of a tumor, triggering a powerful, widespread immune response that kills cancer cells far outside the virus - infected region.

10/7/2008 Novel Lung Cancer Vaccine Trial Launched at Moores UCSD Cancer Center Oncologists at the Moores Cancer Center at the University of California, San Diego (UCSD) in La Jolla are hoping to stave off the relentless march of advanced lung cancer by treating patients with a novel kind of cancer vaccine.

Because of this unique talent, DCs are now a major focus of laboratory and clinical study across the globe, and are critical targets in cancer vaccine development.

In addition, it was increasingly recognized that oncolytic viruses not only were able to directly lyse cancer cells, but they also «freed «tumor specific neoantigens, indirectly acting as a cancer vaccine.

New KRAS cancer vaccine DC named, mRNA - 5671: Moderna has named a novel cancer vaccine DC that encodes for KRAS epitopes.

This morning, we announced that we have dosed our first patient in the Phase 1 study of our personalized cancer vaccine, mRNA - 4157.

CRI: How did you learn about the cancer vaccine trial at Roswell Park?

The trial was part of the Cancer Vaccine Collaborative, a joint program between the Cancer Research Institute and the Ludwig Institute for Cancer Research to develop therapeutic cancer vaccines.

That's what the lead researcher of a study of a breast cancer vaccine in mice would like you to think.

Dendreon (Nasdaq: DNDN, US) Last year we watched how the first cell cancer vaccine was feeling on the market.

The cancer vaccine is the first to show a survival benefit in a phase III trial, conferring a four - month overall survival advantage in men with advanced castrate - resistant prostate cancer.

Drew Pardoll, Glenn Dranoff, Elizabeth Jaffee, Hyam Levitsky, and colleagues conduct preclinical studies showing that a vaccine composed of tumor cells irradiated and genetically modified to produce immune system growth factor GM - CSF (granulocyte - macrophage colony - stimulating factor)-- which would become known as the therapeutic cancer vaccine GVAX — could induce potent, specific, and long - lasting anti-tumor immunity in multiple mouse tumor models.

It is critical to understand how best to design a cancer vaccine such that it recognizes only the tumor without inducing an equally destructive autoimmune response to normal issue.

Dr. Khleif serves on many local, national, and international committees and as a cancer vaccine expert for a number of national organizations.

One approach that he and other researchers have considered is a cancer vaccine.

With enthusiasm for cancer immunotherapy mounting thanks to recent successes in the clinic with immune - based cancer treatments such as anti-CTLA-4 and anti-PD-1 antibodies, and the FDA approvals of sipuleucel - T prostate cancer vaccine and ipilimumab for the treatment of melanoma, and in light of the many promising immunotherapies now in clinical trials with potential for near - term FDA approval, the Cancer Research Institute launched the first annual Cancer Immunotherapy Awareness Month in June 2013 as a way to increase public awareness of the power of immunotherapy to revolutionize cancer treatment and of the need for continued public support for research to bring these treatments to more patients sooner.

New Jersey Researcher Given Grant to Study the Possibilities of a Breast Cancer Vaccine The Star - Ledger, NJ.com - February 11, 2013